Marc Ballas
Research Subjects
Marc Ballas has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Danny Rischin
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
111 shared publications - Michael Chisamore
13Merck & Co., Inc., Rahway, New Jersey
111 shared publications - Catherine Ellis
GSK, Collegeville, USA
110 shared publications - Axel Hoos
Scorpion Therapeutics, Boston, Massachusetts
96 shared publications - David C. Turner
Clinical Pharmacology Genentech South San Francisco California USA
96 shared publications - Jafar Sadik Shaik
GSK, Collegeville, Pennsylvania
96 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of TTD in pain and physical function (mITT population and PD-L1 CPS≥20 subgroup)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of TTD in pain and physical function (mITT population and PD-L1 CPS≥20 subgroup)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of AEs by maximum severity grade (Safety population)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of AEs by maximum severity grade (Safety population)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Comparison of baseline germline genetic biomarkers between treatment arms (post-hoc analyses)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Comparison of baseline germline genetic biomarkers between treatment arms (post-hoc analyses)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Tumor gene expression and genomic profiling (post-hoc analyses)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Tumor gene expression and genomic profiling (post-hoc analyses)
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study design. *Patients randomized after the date of DIL who were unable to receive feladilimab/placebo were excluded from the mITT population but included in the safety population; †more than one reason could be selected; AE, adverse event; DIL, Dear Investigator Letter; ITT, intention to treat; mITT, modified ITT.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Study design. *Patients randomized after the date of DIL who were unable to receive feladilimab/placebo were excluded from the mITT population but included in the safety population; †more than one reason could be selected; AE, adverse event; DIL, Dear Investigator Letter; ITT, intention to treat; mITT, modified ITT.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Patient outcomes by baseline ctDNA and molecular response (post hoc analyses). A, PFS Kaplan–Meier curves for the BEP1 stratified by baseline ctDNA. B, PFS treatment responses in patients stratified by baseline ctDNA level, adjusted for PD-L1 and HPV status. C, PFS Kaplan–Meier curves for the BEP2 stratified by molecular responder status at week 15. D, BOR distribution across treatment groups. BEP1 is defined as all patients with a baseline sample, and the BEP2 is defined as all patients with both a baseline and week 15 sample. ctDNA high and low are defined as mVAF ≥ 1.33% and <1.33%, respectively. Molecular responders and nonresponders are defined as patients with a reduction from baseline at week 15 in ctDNA of ≥50% and <50%, respectively. AIC, Akaike information criterion; BOR, best overall response; MNR, molecular nonresponder; MR, molecular responder; PD, progressive disease; SD, stable disease.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Patient outcomes by baseline ctDNA and molecular response (post hoc analyses). A, PFS Kaplan–Meier curves for the BEP1 stratified by baseline ctDNA. B, PFS treatment responses in patients stratified by baseline ctDNA level, adjusted for PD-L1 and HPV status. C, PFS Kaplan–Meier curves for the BEP2 stratified by molecular responder status at week 15. D, BOR distribution across treatment groups. BEP1 is defined as all patients with a baseline sample, and the BEP2 is defined as all patients with both a baseline and week 15 sample. ctDNA high and low are defined as mVAF ≥ 1.33% and <1.33%, respectively. Molecular responders and nonresponders are defined as patients with a reduction from baseline at week 15 in ctDNA of ≥50% and <50%, respectively. AIC, Akaike information criterion; BOR, best overall response; MNR, molecular nonresponder; MR, molecular responder; PD, progressive disease; SD, stable disease.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Baseline demographics and disease characteristics (mITT population).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Baseline demographics and disease characteristics (mITT population).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of investigator-assessed best response without confirmation (mITT population and PD-L1 CPS ≥ 20 subgroup).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Summary of investigator-assessed best response without confirmation (mITT population and PD-L1 CPS ≥ 20 subgroup).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
OS and PFS for the mITT population (A and C) and the PD-L1 CPS ≥ 20 subgroup (B and D). Data cutoff: April 27, 2021. The mITT population included all randomized patients who received the study intervention, whether or not randomized, but excluded those who were first dosed or randomized after the date of requesting immediate discontinuation of feladilimab and placebo. CI, confidence interval; HR, hazard ratio; mITT, modified intention-to-treat; OS, overall survival; PD-L1 CPS, programmed cell death ligand-1 combined positive score; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
OS and PFS for the mITT population (A and C) and the PD-L1 CPS ≥ 20 subgroup (B and D). Data cutoff: April 27, 2021. The mITT population included all randomized patients who received the study intervention, whether or not randomized, but excluded those who were first dosed or randomized after the date of requesting immediate discontinuation of feladilimab and placebo. CI, confidence interval; HR, hazard ratio; mITT, modified intention-to-treat; OS, overall survival; PD-L1 CPS, programmed cell death ligand-1 combined positive score; PFS, progression-free survival; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
HLA pharmacogenetic analyses in patients treated with pembrolizumab + placebo (mITT population; post-hoc analyses)
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
HLA pharmacogenetic analyses in patients treated with pembrolizumab + placebo (mITT population; post-hoc analyses)